Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

The U.S. IPO market looks to be gathering steam, with a few names springing up that are attracting investor attention.